| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 7, 2026 | ±3.1% | +1.2% | over-priced |
| November 7, 2025 | ±2.4% | +1.3% | over-priced |
| August 8, 2025 | ±2.7% | +1.9% | over-priced |
| May 8, 2025 | ±3.3% | -1.5% | over-priced |
| November 8, 2024 | ±3.7% | -0.4% | over-priced |
| August 8, 2024 | ±2.8% | +3.0% | under-priced |
| May 8, 2024 | ±2.0% | -0.0% | over-priced |
| November 8, 2023 | ±2.1% | -0.4% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $5.65 | $4.5B | $359M |
| Q4 FY2025 | $7.03 | $4.5B | $448M |
| Q3 FY2025 | $5.86 | $4.5B | $379M |
| Q2 FY2025 | $5.43 | $4.3B | $363M |
Universal Health Services, Inc. Class B (UHS) reports in 99 days, with the next report estimated for September 20, 2026. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 1.2% on average — the market has systematically over-priced UHS's earnings risk. Fundamentals into the print: EPS up 17.7% year-over-year, revenue up 9.6%. QuantLogix's live 5-factor engine currently reads UHS as a neutral at 46/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →